Abstract: A system and method enables the determination of the probably that a subject has or will develop breast cancer by obtaining spectral data of a selected biomarker from a first region of the subject's breast of presumably healthy breast tissue, the level of the biomarker having a correlation with the presence or probability of development of a breast tumor in a second region of the breast difference from the first region. The system and method may also be used for other organs, such as brain, ovary, kidney, and prostate.

Abstract: A method and system for monitoring therapeutic interventions for treating a patient with PTSD comprises using a scanner to obtain pre-treatment neural spectroscopic data of at least one neuromarker chemical in the brain of the patient before treatment, treating the patient with at least one treatment protocol, after treatment, obtaining post-treatment neural spectroscopic data of the at least one neuromarker chemical in the brain of the patient, and comparing the results of the pre-treatment and post-treatment data to enable a determination of the effectiveness of the treatment.

Abstract: The present invention relates to an MRS 1D or 2D method and system for obtaining spectral data of the brain of a subject and using neurochemical markers to enable whether a subject is experiencing acute pain, and providing the capacity to monitor response to therapy on an individual basis. The markers can be an increase of Fuc II, III, IV, VII and lactate.

Abstract: A method and system enabling a determination of the risk of developing breast cancer of a subject, comprises using a magnetic resonance spectroscopy device to obtain the level of the spectral signal at 3.15 and 3.19 ppm, within the breast tissue of the subject, and comparing the level of the spectral signal obtained in the first step with a reference level of a spectral signal at 3.15 and 3.19 ppm of the breast of a healthy subject, to determine whether the level of the signal obtained in the first step exceeds the reference level of a healthy subject is comparable to that of a subject known to be at elevated risk; or is elevated to the level of persons known to be carrying a gene mutation.

Abstract: An integrated MRI and MRS system includes a plurality of different classifiers for detecting the likelihood of the new data to be one of the different diseases/conditions in different body organs, and even the progression of the disease, disease state and condition within that organ. An interface module receives information on the individual including region of the body and potential disease/condition; and provides this information to a data analysis unit which automatically dictates which coil, the scanning protocol and classifier.